BCO Pharma is a late development stage healthcare company that develops products for the unique needs of pediatric or other vulnerable patient populations. The company's lead product is a unique pediatric formulation of an inotrope that is used to treat hypotension in critically ill babies and children. The phase III trial supporting the product is now finished and an application for a marketing authorization in the EU will be submitted in August of 2022.